The combination of alpelisib, a selective PIK3CA inhibitor, with mTOR inhibitors has also shown a synergistic efficacy in PIK3CA-mutated (H1047R) hepatocellular carcinoma (98). This evidence concerns the gene MTOR and hepatocellular carcinoma.